Scarica l'app Stockscreener
1.185
4.44%
-0.055
Precedente Chiudi:
$1.24
Aprire:
$1.22
Volume 24 ore:
1.50M
Relative Volume:
1.05
Capitalizzazione di mercato:
$147.53M
Reddito:
$1.55M
Utile/perdita netta:
$-63.06M
Rapporto P/E:
-1.4889
EPS:
-0.7959
Flusso di cassa netto:
$-49.45M
1 W Prestazione:
-7.42%
1M Prestazione:
-9.54%
6M Prestazione:
-42.20%
1 anno Prestazione:
-28.18%
Intervallo 1D:
$1.17
$1.25
Intervallo di 1 settimana:
$1.17
$1.32
Portata 52W:
$1.00
$3.06
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Nome
Milestone Pharmaceuticals Inc
Settore
Industria
Telefono
(514) 336-0444
Indirizzo
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.185 | 154.38M | 1.55M | -63.06M | -49.45M | -0.7959 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Strong Buy |
| 2025-12-15 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-09-11 | Iniziato | Wells Fargo | Overweight |
| 2025-06-05 | Ripresa | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-06-20 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-25 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Iniziato | Oppenheimer | Outperform |
| 2019-06-03 | Iniziato | Cowen | Outperform |
| 2019-06-03 | Iniziato | Jefferies | Buy |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
Price to book forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Milestone Pharmaceuticals Inc (MIST) Institutional Confidence - TradingKey
Milestone Pharmaceuticals (MIST) Investor update Summary - Quartr
Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org - AOL.com
Milestone Pharmaceuticals (MIST) Slips 2.3% as Shares Test Key Support LevelsBuy Signal Reports - DonanımHaber
Milestone lures six new employees with 288,000 options - Stock Titan
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Price to sales forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Price to sales forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Enterprise value to revenue forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Price to earnings forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Milestone Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIST) - TradingView
MIST Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 - TMX Newsfile
Milestone Pharmaceuticals StockSunday background on the cardiac drug developer - ad-hoc-news.de
Milestone Pharmaceuticals Inc (MIST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Milestone Pharmaceuticals Inc - TradingKey
Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Milestone Pharmaceuticals Inc (MIST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Milestone Pharmaceuticals Inc (MIST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Milestone Pharmaceuticals Inc (MIST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Milestone Pharmaceuticals Inc (MIST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Milestone Pharmaceuticals Inc (MIST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Milestone Pharmaceuticals (MIST) Climbs Over 5%: Biotech Stock Breaks Above Key Support ZoneDebt Free Companies - dars.gov.et
Milestone Pharmaceuticals Shareholders Approve Governance and Compensation Measures - The Globe and Mail
Milestone Pharmaceuticals Faces Financial Challenges amidst Market Shifts - timothysykes.com
Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwC - Stock Titan
Milestone (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 strike - Stock Titan
Milestone Pharmaceuticals (MIST) awards director 77,000 stock options - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 - Stock Titan
Director at Milestone Pharmaceuticals (MIST) receives 77,000 stock options at $1.22 - Stock Titan
Milestone Pharmaceuticals (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives grant of 77,000 stock options - Stock Titan
Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST) - Seeking Alpha
Milestone Pharmaceuticals remains a Strong Buy despite 37% stock drop post-FDA approval of Cardamyst - Pluang
Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets) - Newswire Canada
Milestone Pharmaceuticals: Taking The Long View (NASDAQ:MIST) - Seeking Alpha
Eli Lilly scores a first in major pharma milestone - thestreet.com
Wockhardt's Zaynich wins US FDA approval, marking milestone in antibiotic innovation - Business Today
Milestone (MIST) Q1 2026 Earnings Transcript - The Globe and Mail
Milestone Pharmaceuticals Inc. Q1 2026 Earnings: Significant EPS Miss as Pre-Revenue Biotech Continues DevelopmentRevenue Growth Outlook - dars.gov.et
MISTMilestone Pharmaceuticals Inc Stock Price and Quote - Finviz
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - PR Newswire
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
[EFFECT] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
H.C. Wainwright Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals (MIST) Slides 7.24% as Selling Pressure Builds—Key Support at $1.34 in FocusOBV Divergence - thelegaladvocate.com
Milestone Pharmaceuticals Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider Loss Than ExpectedEPS Growth Rate - dars.gov.et
Milestone Pharmaceuticals Inc Azioni (MIST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
2.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):